Genelux (NASDAQ:GNLX) Shares Down 1.3% – What’s Next?

Genelux Co. (NASDAQ:GNLX) fell 1.3% on Friday . The stock traded as low as $3.76 and last traded at $3.93. 93,061 shares traded hands during trading, a decline of 53% from the average session volume of 199,940 shares. The stock had previously closed at $3.98.

Genelux Price Performance

The company has a fifty day simple moving average of $3.97 and a two-hundred day simple moving average of $3.08. The company has a market capitalization of $135.73 million, a P/E ratio of -4.14 and a beta of -1.41.

Hedge Funds Weigh In On Genelux

Several institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP grew its position in shares of Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after purchasing an additional 52,958 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Genelux in the fourth quarter valued at about $41,000. LPL Financial LLC grew its position in shares of Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after purchasing an additional 39,516 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Genelux in the fourth quarter valued at about $25,000. Finally, LifeSteps Financial Inc. grew its position in shares of Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after purchasing an additional 8,715 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.